Local news. A brighter tomorrow.← Company DirectoryBloomington, Indiana
Biologics development and manufacturing operation in Bloomington.
Selected staff and leaders listed by the company. Checked Oct 16, 2026 · Next source review Nov 15, 2026.
Company-wide, Indiana, local and parent figures are shown separately. Reporting dates may be older than the date checked. Unavailable figures remain unverified.
Company-issued releases from the past 90 days. Company claims have not been independently verified.
Catalent announced a U.S. program designed to take complex biologic molecules from a gene sequence to released drug substance in 10 months. The company says the offering combines cell-line development with its U.S. development and manufacturing network; the announcement does not identify a Bloomington expansion.
Read original release ↗Catalent announced a $4.1 billion equivalent term loan and a $600 million revolving credit facility. The company expects about $100 million in annual interest savings. This is a corporate financing announcement, not a Bloomington-specific investment.
Read original release ↗In a corporate announcement, Catalent and Taysha said they expanded their partnership for investigational Rett syndrome therapy TSHA-102, subject to potential FDA approval. The planned manufacturing is in Harmans, Maryland; this release does not announce a Bloomington project.
Read original release ↗
